AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36092959 — intervention group
Group type: COMPARATOR
Intervention: Conventional antimicrobial therapy (sulbactam plus cefoperazone)
Number of subjects: 65
Study 32779012 — intervention group
Group type: EXPERIMENTAL
Intervention: Static-guided (SG) access group
Number of subjects: 30
Study 32779012 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 34331838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulization and meibomian gland massage (NB group)
Number of subjects: 38
Study 34331838 — intervention group
Group type: COMPARATOR
Intervention: Eye drop group (ED group)
Number of subjects: 38
Study 33288477 — intervention group
Group type: EXPERIMENTAL
Intervention: Geri-medium
Number of subjects: 181
Study 33288477 — intervention group
Group type: COMPARATOR
Intervention: CSCM
Number of subjects: 181
Study 33288477 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic testing for aneuploidy (Geri-medium)
Number of subjects: 181
Study 33288477 — intervention group
Group type: COMPARATOR
Intervention: Preimplantation genetic testing for aneuploidy (CSCM)
Number of subjects: 181
Study 33288477 — intervention group
Group type: EXPERIMENTAL
Intervention: Untested transfers (Geri-medium)
Number of subjects: 181
Study 33288477 — intervention group
Group type: COMPARATOR
Intervention: Untested transfers (CSCM)
Number of subjects: 181
Study 36205225 — intervention group
Group type: EXPERIMENTAL
Intervention: PARTNER intervention (centralised Care Support Team for 12 months)
Number of subjects: 217
Study 36205225 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 217
Study 32805144 — intervention group
Group type: EXPERIMENTAL
Intervention: Jatropha curcas with compost amendments
Number of subjects: 3
Study 32805144 — intervention group
Group type: EXPERIMENTAL
Intervention: Vetiveria zizanioides with compost amendments
Number of subjects: 3
Study 32805144 — intervention group
Group type: COMPARATOR
Intervention: Compost amendments
Number of subjects: 3
Study 32805144 — intervention group
Group type: COMPARATOR
Intervention: Contaminated soils
Number of subjects: 3
Study 32805144 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil amendments
Number of subjects: 3
Study 35251715 — intervention group
Group type: EXPERIMENTAL
Intervention: Maze control training in addition to selected conventional physical therapy
Number of subjects: 30
Study 34412897 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional light curing after finishing and polishing
Number of subjects: 80
Study 34412897 — intervention group
Group type: COMPARATOR
Intervention: No polishing (nonpolished)
Number of subjects: 80
Study 34412897 — intervention group
Group type: EXPERIMENTAL
Intervention: Polishing with aluminum oxide discs (polished)
Number of subjects: 80
Study 32888454 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus etoposide (six cycles of intravenous carboplatin [AUC 5 mg/mL per min] on day 1 plus intravenous etoposide [100 mg/m2 from day 1 to day 3])
Number of subjects: 164
Study 32888454 — intervention group
Group type: COMPARATOR
Intervention: Topotecan (2.3 mg/m2 from day 1 to day 5, for six cycles)
Number of subjects: 164
Study 32888454 — intervention group
Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 164
Study 32888454 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus etoposide
Number of subjects: 164
Study 33078917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity direct current (LIDC)
Number of subjects: 32
Study 33078917 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 32
Study 33043659 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB + MVR
Number of subjects: 53
Study 33043659 — intervention group
Group type: COMPARATOR
Intervention: ONCAB + MVR
Number of subjects: 53
Study 34968693 — intervention group
Group type: EXPERIMENTAL
Intervention: BIO-RSA
Number of subjects: 41
Study 34968693 — intervention group
Group type: COMPARATOR
Intervention: Metal-augmented baseplates
Number of subjects: 41
Study 33618124 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Training (ABMT) with low working memory load (WML)
Number of subjects: 306
Study 33618124 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Training (ABMT) with high working memory load (WML)
Number of subjects: 306
Study 33618124 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Training (ABMT) with no working memory load (WML)
Number of subjects: 306
Study 32986176 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg/12 h or 2.5 mg/12 h (after dose adjustment or in high-risk patients)
Number of subjects: 160
Study 32986176 — intervention group
Group type: COMPARATOR
Intervention: DAPT with aspirin and clopidogrel
Number of subjects: 160
Study 35487099 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral hand orientation with directional feedback
Number of subjects: 30
Study 35487099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronated hand orientation with directional feedback
Number of subjects: 30
Study 35487099 — intervention group
Group type: COMPARATOR
Intervention: Aiming errors without feedback
Number of subjects: 30
Study 35487099 — intervention group
Group type: EXPERIMENTAL
Intervention: Aiming errors with feedback
Number of subjects: 30
Study 33228726 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan potassium plus Keluoxin capsule (KLX)
Number of subjects: 252
Study 33228726 — intervention group
Group type: COMPARATOR
Intervention: losartan potassium plus placebo
Number of subjects: 252
Study 34480868 — intervention group
Group type: EXPERIMENTAL
Intervention: ERP (Exposure and Response Prevention)
Number of subjects: 224
Study 34480868 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (active control)
Number of subjects: 224
Study 34480868 — intervention group
Group type: EXPERIMENTAL
Intervention: ERP
Number of subjects: 224
Study 34480868 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 224
Study 32925743 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 1000 mg in 100 mL normal saline, administered intravenously over 20 minutes before skin incision
Number of subjects: 80
Study 32925743 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 80
Study 36180134 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 38
Study 36180134 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 33246887 — intervention group
Group type: EXPERIMENTAL
Intervention: olesoxime
Number of subjects: 0
Study 35658024 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 2539
Study 35658024 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 2539
Study 35658024 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 2539
Study 35658024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2539
Study 32966877 — intervention group
Group type: EXPERIMENTAL
Intervention: GWL Pack featuring 1 of 3 rotating images added to blank pack
Number of subjects: 359
Study 32966877 — intervention group
Group type: COMPARATOR
Intervention: Blank Pack devoid of any cigarette branding
Number of subjects: 359
Study 32966877 — intervention group
Group type: COMPARATOR
Intervention: Standard US Pack
Number of subjects: 359
Study 35650562 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer worker role
Number of subjects: 32
Study 33678522 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg IV plus Bevacizumab 15 mg/kg IV every 3 weeks
Number of subjects: 103
Study 33678522 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib monotherapy
Number of subjects: 103
Study 33678522 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab monotherapy
Number of subjects: 103
Study 32530550 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida antigen
Number of subjects: 120
Study 32530550 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD
Number of subjects: 120
Study 32530550 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR
Number of subjects: 120
Study 34487440 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic cardioversion before electrical cardioversion
Number of subjects: 0
Study 34487440 — intervention group
Group type: COMPARATOR
Intervention: Electrical cardioversion
Number of subjects: 0
Study 32394219 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-based face-to-face (n=65; six group sessions led by a psychologist)
Number of subjects: 204
Study 32394219 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-based mobile (n=73; one group session and mobile app)
Number of subjects: 204
Study 32394219 — intervention group
Group type: COMPARATOR
Intervention: Control (n=66; only the measurements)
Number of subjects: 204
Study 35436230 — intervention group
Group type: EXPERIMENTAL
Intervention: USSD-based app
Number of subjects: 300
Study 35436230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SRH information)
Number of subjects: 300
Study 34251103 — intervention group
Group type: EXPERIMENTAL
Intervention: Longidaza (rectal suppositories of 3000 IU)
Number of subjects: 202
Study 34251103 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard postoperative therapy with tamsulosin and fluoroquinolone)
Number of subjects: 202
Study 32862662 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 398
Study 32862662 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 398
Study 35906579 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based or partly supervised exercise programme lasting 2–3 months
Number of subjects: 79
Study 33177434 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered cognitive behavioral intervention (CBI) for 10 weeks
Number of subjects: 140
Study 33177434 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up (Control)
Number of subjects: 140
Study 32883033 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-derived protein
Number of subjects: 0
Study 32883033 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-derived protein
Number of subjects: 0
Study 32883033 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-derived protein
Number of subjects: 0
Study 32883033 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended dietary proteins (animal, plant, collagen)
Number of subjects: 0
Study 35045820 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Childbirth and Parenting (MBCP)
Number of subjects: 111
Study 35045820 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care as usual (ECAU)
Number of subjects: 111
Study 616886749 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound azintamide enteric‐coated tablets
Number of subjects: 90
Study 616886749 — intervention group
Group type: COMPARATOR
Intervention: Compound digestive enzyme capsules
Number of subjects: 90
Study 35535490 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital storytelling‐legacy intervention
Number of subjects: 150
Study 35535490 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 150
Study 33369909 — intervention group
Group type: EXPERIMENTAL
Intervention: Leu/Met/Sil 1.0
Number of subjects: 267
Study 33369909 — intervention group
Group type: EXPERIMENTAL
Intervention: Leu/Met/Sil 4.0
Number of subjects: 267
Study 33369909 — intervention group
Group type: EXPERIMENTAL
Intervention: Leu/Sil 4.0
Number of subjects: 267
Study 33369909 — intervention group
Group type: EXPERIMENTAL
Intervention: Leu/Met/Sil 1.0 in African Americans
Number of subjects: 267
Study 33369909 — intervention group
Group type: EXPERIMENTAL
Intervention: Leu/Met/Sil 1.0 in participants with BMI <40 kg/m2
Number of subjects: 267
Study 33369909 — intervention group
Group type: EXPERIMENTAL
Intervention: Leu/Met/Sil 1.0 in participants with baseline insulin ≥12mU/L
Number of subjects: 267
Study 32706658 — intervention group
Group type: EXPERIMENTAL
Intervention: HUS‐iCBT plus add‐on scheduled telephone support (STS)
Number of subjects: 100
Study 32706658 — intervention group
Group type: COMPARATOR
Intervention: HUS‐iCBT as usual (control group)
Number of subjects: 100
Study 34789403 — intervention group
Group type: EXPERIMENTAL
Intervention: ap1gen (low-dose recombinant pertussis-only vaccine containing 1 μg PTgen and 1 μg FHA)
Number of subjects: 250
Study 34789403 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap1gen (tetanus, reduced-dose diphtheria combined to ap1gen)
Number of subjects: 250
Study 34789403 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap2gen (combined to recombinant pertussis containing 2 μg PTgen and 5 μg FHA)
Number of subjects: 250
Study 34789403 — intervention group
Group type: EXPERIMENTAL
Intervention: TdaP5gen (licensed recombinant TdaP vaccine containing 5 μg PTgen and 5 μg FHA)
Number of subjects: 250
Study 34789403 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap8chem (licensed Tdap vaccine containing 8 μg of chemically inactivated pertussis toxoid, 8 μg FHA, and 2.5 μg pertactin)
Number of subjects: 250
Study 34160577 — intervention group
Group type: EXPERIMENTAL
Intervention: NCRT plus surgery
Number of subjects: 451
Study 34160577 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 451
Study 34904247 — intervention group
Group type: EXPERIMENTAL
Intervention: GIC (Equia Forte® ‐ GC Corp)
Number of subjects: 182
Study 34904247 — intervention group
Group type: COMPARATOR
Intervention: GCR (Beautifil Bulk Restorative® ‐ Shofu Inc)
Number of subjects: 182
Study 34536187 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 1983
Study 33806809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse reproductive health app
Number of subjects: 1013
Study 33806809 — intervention group
Group type: COMPARATOR
Intervention: General health control app
Number of subjects: 1013
Study 32679238 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment plus usual care
Number of subjects: 2687
Study 32679238 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 2687
Study 35343648 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m2 once-a-week with radiotherapy
Number of subjects: 300
Study 35343648 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 once every-3-weeks with radiotherapy
Number of subjects: 300
Study 34059488 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide treatment
Number of subjects: 3894
Study 36496358 — intervention group
Group type: EXPERIMENTAL
Intervention: Instagram-based vaping cessation intervention (up to 3 posts per weekday for 25 days over 5 weeks)
Number of subjects: 0
Study 36496358 — intervention group
Group type: COMPARATOR
Intervention: Control group directed to kickitca.org (website offering cessation services)
Number of subjects: 0
Study 34533786 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg every 2 weeks
Number of subjects: 0
Study 34533786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32532291 — intervention group
Group type: EXPERIMENTAL
Intervention: Enadenotucirev (EnAd) in combination with chemoradiotherapy
Number of subjects: 30
Study 36422808 — intervention group
Group type: EXPERIMENTAL
Intervention: Levotiroxina MK® (test product)
Number of subjects: 80
Study 36422808 — intervention group
Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 80
Study 34453840 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation + CRT
Number of subjects: 133
Study 34453840 — intervention group
Group type: COMPARATOR
Intervention: Drug (pharmacological rate control)
Number of subjects: 133
Study 33520069 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility to smoke cigarettes
Number of subjects: 830
Study 33520069 — intervention group
Group type: EXPERIMENTAL
Intervention: Future intention to smoke cigarettes
Number of subjects: 830
Study 33520069 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of susceptibility
Number of subjects: 830
Study 33520069 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of future intention to smoke
Number of subjects: 830
Study 35119113 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused psychoeducation (SFP)
Number of subjects: 119
Study 35119113 — intervention group
Group type: EXPERIMENTAL
Intervention: Childbirth preparation training (CPT)
Number of subjects: 119
Study 35119113 — intervention group
Group type: COMPARATOR
Intervention: Control group care
Number of subjects: 119
Study 34381612 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency (PRF)
Number of subjects: 69
Study 34381612 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal Radiofrequency (RF)
Number of subjects: 69
Study 34381612 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 69
Study 32491964 — intervention group
Group type: EXPERIMENTAL
Intervention: Michigan occlusal splint (G1)
Number of subjects: 30
Study 32491964 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) (G2)
Number of subjects: 30
Study 32491964 — intervention group
Group type: COMPARATOR
Intervention: LLLT placebo (G3)
Number of subjects: 30
Study 32741710 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) with core decompression (CD)
Number of subjects: 40
Study 32741710 — intervention group
Group type: COMPARATOR
Intervention: Core decompression (CD) only
Number of subjects: 40
Study 34184823 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Number of subjects: 71000
Study 32955801 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine prophylaxis
Number of subjects: 785
Study 32955801 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trial (RCT)
Number of subjects: 785
Study 34802083 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (LAH)
Number of subjects: 4039
Study 34535959 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine supplementation (7 g twice daily for 4 months)
Number of subjects: 27
Study 34535959 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (7 g twice daily for 4 months)
Number of subjects: 27
Study 34535959 — intervention group
Group type: COMPARATOR
Intervention: Comparison of glycine and BCAA
Number of subjects: 27
Study 36494793 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial microstimulation (EM)
Number of subjects: 90
Study 36494793 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 33723086 — intervention group
Group type: EXPERIMENTAL
Intervention: Axxess bifurcation device (Biosensors) in combination with Absorb BVS (Abbott Vascular)
Number of subjects: 15
Study 33723086 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-T strategy using Absorb BVS
Number of subjects: 15
Study 33723086 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study 33364598 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 42
Study 33364598 — intervention group
Group type: COMPARATOR
Intervention: non-efavirenz
Number of subjects: 42
Study 34155957 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical double-layer uterine closure
Number of subjects: 120
Study 34155957 — intervention group
Group type: EXPERIMENTAL
Intervention: Purse-string double-layer uterine closure (Turan)
Number of subjects: 120
Study 34155957 — intervention group
Group type: EXPERIMENTAL
Intervention: Double layer step up-step down technique
Number of subjects: 120
Study 34099322 — intervention group
Group type: EXPERIMENTAL
Intervention: StrataGraft
Number of subjects: 71
Study 34099322 — intervention group
Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 71
Study 32431162 — intervention group
Group type: EXPERIMENTAL
Intervention: TeachTown:Basics
Number of subjects: 0
Study 32431162 — intervention group
Group type: COMPARATOR
Intervention: No access to TeachTown:Basics (Control)
Number of subjects: 0
Study 35704479 — intervention group
Group type: EXPERIMENTAL
Intervention: HSIL treatment (including office-based ablative procedures, ablation or excision under anesthesia, or topical fluorouracil or imiquimod)
Number of subjects: 4446
Study 35704479 — intervention group
Group type: COMPARATOR
Intervention: Active monitoring without treatment
Number of subjects: 4446
Study 32700955 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Executive Training (CET)
Number of subjects: 54
Study 32700955 — intervention group
Group type: COMPARATOR
Intervention: Inhibitory Control Training (ICT)
Number of subjects: 54
Study 36373654 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAE
Number of subjects: 562
Study 36373654 — intervention group
Group type: COMPARATOR
Intervention: No LAAE
Number of subjects: 562
Study 36373654 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC
Number of subjects: 562
Study 33210771 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading protocol (test group)
Number of subjects: 34
Study 33210771 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading protocol (control group)
Number of subjects: 34
Study 36031439 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA (10 mg/kg bolus dose 15 min prior to incision and another similar dose after 3 h)
Number of subjects: 63
Study 36031439 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline, same volume as TXA)
Number of subjects: 63
Study 36031439 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA
Number of subjects: 63
Study 36031439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 34063276 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics stimulation (SG)
Number of subjects: 69
Study 34063276 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 69
Study 35212877 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message-based communication intervention
Number of subjects: 100
Study 33388990 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary site surgery
Number of subjects: 923
Study 33388990 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation
Number of subjects: 923
Study 33388990 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 923
Study 33388990 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 923
Study 33388990 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 923